Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 4/20 | 0.45 |
| ▸ | MAOB | P27338 | 4/20 | 0.45 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.43 |
| ▸ | HSD17B2 | P37059 | 4/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7592025 | 0.81 | MAOA (0.44) | MAOAMAOBMDM2HSD17B2RIPK1 | |
| SCHEMBL7592028 | 0.81 | MAOA (0.44) | MAOAMAOBMDM2HSD17B2RIPK1 | |
| SCHEMBL6985685 | 0.77 | RIPK1 (0.44) | MAOAMAOBRIPK1PRKCZ | |
| SCHEMBL7589602 | 0.71 | CHRNA7 (0.45) | CHRNA7MAOAMAOBMDM2HSD17B2 | |
| SCHEMBL7589609 | 0.71 | CHRNA7 (0.45) | CHRNA7MAOAMAOBMDM2HSD17B2 | |
| SCHEMBL27686338 | 0.71 | CHRNA7 (0.47) | CHRNA7MAOAMAOBMDM2HSD17B2 | |
| SCHEMBL16181380 | 0.71 | MDM2 (0.48) | CHRNA7MAOAMAOBMDM2HSD17B2 | |
| SCHEMBL6981391 | 0.70 | MAPT (0.43) | MDM2SLC6A2SLC6A3 | |
| SCHEMBL6985757 | 0.70 | MAPT (0.43) | MDM2SLC6A2SLC6A3 | |
| SCHEMBL6978662 | 0.70 | MAPT (0.43) | MDM2SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1145612-C | New 1- aza-2-alkyl-6-aryl-cyclanes compound, its producing process and medical composition containing them | — | 2004-04-14 | — | — | CN | disclosed |
| EP-1050530-B1 | 1-Aza-2-alkyl-6-aryl-cycloalkanes usefull as memory enhancers | SERVIER LAB (FR) | 2003-10-22 | — | — | EP | disclosed |
| US-6451789-B1 | CENTRAL NERVOUS SYSTEM DISORDERS; COGNITION ACTIVATORS | LES LABORTOIRES SERVIER (FR) | 2002-09-17 | — | — | US | disclosed |
| US-20020042413-A1 | 1-aza-2-alkyl-6-aryl-cycloalkanes | RAULT SYLVAIN (FR) | 2002-04-11 | — | — | US | disclosed |
| US-6323222-B1 | COGNITION ACTIVATORS, ALZHEIMER*S DISEASE AND ENZYME INHIBITORS | ADIR ET COMPAGNIE (FR) | 2001-11-27 | — | — | US | disclosed |
| EP-1050530-A1 | 1-Aza-2-alkyl-6-aryl-cycloalkanes usefull as memory enhancers | ADIR ET COMPAGNIE (FR) | 2000-11-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042413-A1 | 1-aza-2-alkyl-6-aryl-cycloalkanes | SULT2A1, GRIN2A, NR3C1 | CHRNA7 150/4885MAOA 468/4885MAOB 1287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.